US Tech 100

19,564.40

-0.07%

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

ALT

Altimmune (ALT)

Altimmune Inc

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ALT

1 2 3 4 5 6 7 8 9 10 Next >>

Date	Time	Source	Headline	Symbol	Company
09/26/2024	3:45PM	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALT	Altimmune Inc
09/10/2024	12:09PM	GlobeNewswire Inc.	CORRECTION – Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes	NASDAQ:ALT	Altimmune Inc
09/10/2024	6:45AM	GlobeNewswire Inc.	Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes	NASDAQ:ALT	Altimmune Inc
09/03/2024	6:30AM	GlobeNewswire Inc.	Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes	NASDAQ:ALT	Altimmune Inc
08/20/2024	5:05PM	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ALT	Altimmune Inc
08/15/2024	3:14PM	Edgar (US Regulatory)	Form ARS - Annual Report to Security Holders	NASDAQ:ALT	Altimmune Inc
08/15/2024	3:08PM	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:ALT	Altimmune Inc
08/15/2024	3:03PM	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALT	Altimmune Inc
08/08/2024	3:07PM	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ALT	Altimmune Inc
08/08/2024	6:04AM	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALT	Altimmune Inc
08/08/2024	6:00AM	GlobeNewswire Inc.	Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update	NASDAQ:ALT	Altimmune Inc
08/07/2024	6:00AM	GlobeNewswire Inc.	CytoSorbents to Report Second Quarter 2024 Operating and Financial Results	NASDAQ:ALT	Altimmune Inc
08/01/2024	4:47PM	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ALT	Altimmune Inc
08/01/2024	4:45PM	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ALT	Altimmune Inc
08/01/2024	4:43PM	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ALT	Altimmune Inc
08/01/2024	4:40PM	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ALT	Altimmune Inc
08/01/2024	6:30AM	GlobeNewswire Inc.	Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024	NASDAQ:ALT	Altimmune Inc
07/25/2024	6:30AM	GlobeNewswire Inc.	Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology	NASDAQ:ALT	Altimmune Inc
07/03/2024	4:45AM	PR Newswire (US)	Lost Money on Altimmune, Inc.(ALT)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm	NASDAQ:ALT	Altimmune Inc
07/02/2024	6:30AM	GlobeNewswire Inc.	Altimmune to Participate at Leerink Partners Therapeutics Forum	NASDAQ:ALT	Altimmune Inc
06/28/2024	4:45AM	PR Newswire (US)	Lost Money on Altimmune, Inc.(ALT)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm	NASDAQ:ALT	Altimmune Inc
06/26/2024	6:30AM	GlobeNewswire Inc.	Altimmune Mourns Passing of Chief Financial Officer, Richard Eisenstadt	NASDAQ:ALT	Altimmune Inc
06/25/2024	4:45AM	PR Newswire (US)	Shareholders that lost money on Altimmune, Inc.(ALT) should contact The Gross Law Firm about pending Class Action - ALT	NASDAQ:ALT	Altimmune Inc
06/23/2024	12:45PM	GlobeNewswire Inc.	Altimmune Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the American Diabetes Association’s 84th Scientific Sessions	NASDAQ:ALT	Altimmune Inc
06/22/2024	3:45PM	GlobeNewswire Inc.	Altimmune Presents Data on the Effect of Pemvidutide on Cardioinflammatory Lipids during Oral Presentation at American Diabetes Association’s 84th Annual Scientific Sessions	NASDAQ:ALT	Altimmune Inc
06/20/2024	6:30AM	GlobeNewswire Inc.	Altimmune to Participate in the Piper Sandler 2nd Annual Virtual Obesity Investor Day to Discuss ADA Takeaways	NASDAQ:ALT	Altimmune Inc
06/20/2024	4:45AM	PR Newswire (US)	Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before July 5, 2024 to Discuss Your Rights - ALT	NASDAQ:ALT	Altimmune Inc
06/18/2024	6:30AM	GlobeNewswire Inc.	Altimmune Announces Oral Presentations of Pemvidutide Clinical Data at Upcoming American Diabetes Association’s Scientific Sessions	NASDAQ:ALT	Altimmune Inc
06/17/2024	4:45AM	PR Newswire (US)	The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 5, 2024 in Altimmune, Inc. Lawsuit - ALT	NASDAQ:ALT	Altimmune Inc
06/10/2024	4:45AM	PR Newswire (US)	The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 5, 2024 in Altimmune, Inc. Lawsuit - ALT	NASDAQ:ALT	Altimmune Inc